Navigation Links
Sending Real-Money Stipend Payments, a Critical Piece of the Clinical Trial Puzzle at DIA 2013
Date:6/20/2013

Vancouver, BC (PRWEB) June 20, 2013

Chexx Inc., a company that specializes in issuing and sending stipend payments to clinical trial patients around the world, announced today that they will be exhibiting at the DIA 49th Annual Meeting, June 24-26, 2013 in Boston. DIA 2013 will provide an invaluable forum for professionals involved in the discovery, development, and life-cycle management of pharmaceuticals, medical devices, and related products. The event will also include discussion of current and evolving areas such as comparative effectiveness research, health outcomes, and drug/device combination products. As a key international payments provider in the clinical trial space, Chexx Inc. will be on the floor at booth 747, arming attendees with information on how proper payment method plays a role in developing strong relationships with clinical trial participants, increasing goodwill and patient retention.

Chexx Inc. enables research companies to send real-money stipends by international check, EFT or preloaded credit cards in virtually every corner of the globe. “Chexx Inc.’s proven payment disbursement solutions are a powerful tool in strengthening patient relationships in markets around the globe,” says Peter Sampson, VP of Corporate Development for Chexx Inc., “We’re pleased to provide affordable payment options in emerging markets like India, Brazil, Mexico and Malaysia. Sponsors and CROs who want to give their participants the luxury of choice will want to learn about QuickDraw, which allows patients to decide how and where they will be paid.”

The Annual Meeting is intended to strengthen professionals’ understanding of the value of cross-discipline integration and to foster innovation for better health outcomes. Attendees will join more than 7,000 life sciences professionals at all levels and across all disciplines involved in the discovery, development, and life cycle management of medical products all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.

About Chexx Inc.:

Chexx Inc. serves the payment disbursement needs of clinical trial companies, market research companies, international payroll, sales organizations and affiliate managers around the world. For over 17 years they have specialized in providing timely, convenient and cost-effective payouts with excellent results. Chexx Inc. maintains a large network of regional banks to provide payment coverage in over 200 countries. Considerable resources are focused on technical integration and relationship management with each banking partner, resulting in stable global coverage and built in redundancy in key regions.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10856695.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Button Batteries Sending More Kids to ER: Study
2. Sending sexually explicit photos by cell phone -- more common among teens than you might think
3. Synthetic Pot Sending Thousands of Young People to ER: Report
4. Revised geographic adjustments could improve accuracy of Medicare payments, will not solve access, quality problems
5. Awards to 5 IU School of Medicine physicians address critical need for geriatricians
6. Night Staffing With Critical Care Docs May Lower ICU Death Rates
7. Antidepressant use associated with increased mortality among critically ill patients?
8. B2B e Trader is Addressing the Critical Needs of Local Businesses by Lauching the New Shop Small Business Directory
9. US Drug Watchdog Says Its Critical All DePuy Pinnacle Hip Implant Recipients Know The Symptoms Of A Failure And They Offer The Names Of The Best Attorneys For Victims
10. Supporting patient autonomy is critical to improving health
11. ASH launches multi-million-dollar grant program to support critical blood disease research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... ... is proud to announce a new informational post on robotic hair transplantation. San ... Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among the top five states ... And the need for advanced services is growing. , Project WE vs C ... in collaboration with their non-profit partners in their fight against cancer and in support ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design Awards & ... International Social Design Awards. , The 7th A' Social Design Award is ... Institutions worldwide with realized projects and conceptual works. , The first phase of ...
(Date:2/26/2017)... , ... February 26, 2017 , ... NuevaCare, a leading ... diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important upgrade ... Area consumers look for home care close to home, and by having city-specific pages, ...
(Date:2/26/2017)... PA (PRWEB) , ... February 26, 2017 , ... ... and services with Pay-For-Performance B2B Marketing. B2B Sellers will now only pay for B.A.N.T. ... Robert Hennessey, the founder of IndustryArchive.Org, said, “Given the new reality that B2B buyers ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017  A landmark study ... , MBBS, PhD, FRACS, of  Sydney Heart and ... Sydney will be published in the February 28, ... American College of Cardiology . According to the study, which ... bypass surgery technique (anOPCABG) reduced postoperative stroke ...
(Date:2/27/2017)... AUSTIN, Texas , Feb. 27, 2017  International Biophysics ... Austin, Texas , today announced a 34% revenue growth ... a 53% increase in unit sales.  This growth was fueled ... in addition to the expansion of its global ... Shockley, Jr., International Biophysics, CEO, "As we enter our 25 ...
(Date:2/27/2017)... Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... GtreeBNT Co., Ltd., received a positive response from ... trial design for RGN-137 to treat epidermolysis bullosa ... that incorporates Thymosin beta 4 ("Tß4") as the ...
Breaking Medicine Technology: